TXMD TherapeuticsMD, Inc.
Nasdaq · SEC CIK 25743 · EDGAR
- Bought, last 12 months
- $14.0K 1 purchases by 1 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 97 since 2021-07-02, latest 2025-12-29
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Thompson Tommy G | Dir | $14.0K | — |
Transactions 66
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-29 | 2025-12-23 | TXMD | Thompson Tommy G | Dir | P - Purchase | $1.67 | +8,400 | 23.2K | +57% | +$14.0K | |
| 2025-04-15 | 2025-04-14 | TXMD | Walker Marlan D | CEO | P - Purchase | $1.00 | +490 | 73.6K | +0.7% | +$490 | |
| 2025-04-15 | 2025-04-14 | TXMD | Thompson Tommy G | Dir | P - Purchase | $1.00 | +325 | 14.8K | +2% | +$325 | |
| M | 2025-04-10 | 2025-04-09+ | TXMD | Walker Marlan D | CEO | P - Purchase | $0.8649 | +2,303 | 72.0K | +3% | +$1,992 |
| DM | 2025-02-20 | 2025-02-18 | TXMD | Walker Marlan D | CEO | M - OptEx | $0.00 | +8,281 | 66.0K | +14% | $0 |
| D | 2025-02-20 | 2025-02-18 | TXMD | Collins Cooper C. | Dir | M - OptEx | $0.00 | +8,500 | 60.5K | +16% | $0 |
| D | 2025-02-20 | 2025-02-18 | TXMD | Naughton Gail K | Dir | M - OptEx | $0.00 | +8,500 | 8,500 | New | $0 |
| D | 2025-02-20 | 2025-02-18 | TXMD | Thompson Tommy G | Dir | M - OptEx | $0.00 | +8,500 | 14.5K | +143% | $0 |
| 2024-08-26 | 2024-08-22 | TXMD | Collins Cooper C. | Dir | P - Purchase | $1.73 | +4,094 | 52.0K | +9% | +$7,083 | |
| 2024-08-23 | 2024-08-21 | TXMD | Collins Cooper C. | Dir | P - Purchase | $1.70 | +1,200 | 47.9K | +3% | +$2,040 | |
| DM | 2023-12-07 | 2023-12-06+ | TXMD | Walker Marlan D | CEO | S - Sale+OE | $2.29 | -19.1K | 67.1K | -22% | -$43.7K |
| D | 2023-12-07 | 2023-12-05 | TXMD | Walker Marlan D | CEO | M - OptEx | $0.00 | +70.0K | 81.6K | +603% | $0 |
| I | 2023-11-17 | 2023-11-15 | TXMD | Rosen David Efraim | 10% | A - Grant | $2.28 | +877.2K | 2.95M | +42% | +$2.00M |
| 2023-08-21 | 2023-08-17 | TXMD | ZIEGLER JOSEPH | Principal Financial Off | A - Grant | $0.00 | +7,500 | 7,500 | New | $0 | |
| I | 2023-06-29 | 2023-06-28 | TXMD | Rosen David Efraim | Dir, 10%, See Remarks | A - Grant | $3.68 | +312.5K | 2.07M | +18% | +$1.15M |
| DMA | 2023-05-04 | 2023-04-26 | TXMD | Walker Marlan D | CEO | M - OptEx | $0.00 | +2,744 | 14.0K | +24% | $0 |
| DA | 2023-05-04 | 2023-04-26 | TXMD | Walker Marlan D | CEO | S - Sale+OE | $3.64 | -692 | 11.6K | -6% | -$2,519 |
| D | 2023-04-14 | 2023-04-12 | TXMD | Walker Marlan D | CEO | S - Sale+OE | $3.65 | -1,170 | 12.3K | -9% | -$4,270 |
| DM | 2023-04-14 | 2023-04-12 | TXMD | Walker Marlan D | CEO | M - OptEx | $0.00 | +7,508 | 8,999 | +504% | $0 |
| D | 2023-04-14 | 2023-04-12 | TXMD | Donegan Michael C | Prin. Fin, Acctg. Off | M - OptEx | $0.00 | +50.0K | 61.9K | +422% | $0 |
| AI | 2023-02-22 | 2022-12-30 | TXMD | Rubric Capital Management LP | Dir, 10%, See remarks | D - Sale to Iss | $1,333.00 | -29.0K | 0 | -100% | -$38.66M |
| DM | 2023-01-30 | 2023-01-26 | TXMD | Donegan Michael C | Prin. Fin, Acctg. Off | M - OptEx | $0.00 | +5,940 | 13.6K | +78% | $0 |
| DM | 2023-01-30 | 2023-01-26+ | TXMD | Donegan Michael C | Prin. Fin, Acctg. Off | S - Sale+OE | $5.08 | -1,697 | 11.9K | -13% | -$8,621 |
| DM | 2023-01-25 | 2023-01-23 | TXMD | Donegan Michael C | Prin. Fin, Acctg. Off | M - OptEx | $0.00 | +4,365 | 6,519 | +203% | $0 |
| DM | 2023-01-25 | 2023-01-23+ | TXMD | Donegan Michael C | Prin. Fin, Acctg. Off | S - Sale+OE | $5.34 | -1,309 | 7,610 | -15% | -$6,990 |
| I | 2023-01-03 | 2022-12-30 | TXMD | Rubric Capital Management LP | 10% | S - Sale | $1,333.00 | -29.0K | 0 | -100% | -$38.66M |
| I | 2022-12-12 | 2022-12-09 | TXMD | Rubric Capital Management LP | 10% | P - Purchase | $6.09 | +14.8K | 1.76M | +0.9% | +$90.3K |
| D | 2022-12-09 | 2022-12-06 | TXMD | Bernick Brian | Co-CEO | M - OptEx | $0.00 | +3,167 | 5,127 | +162% | $0 |
| DM | 2022-12-09 | 2022-12-06+ | TXMD | Bernick Brian | Co-CEO | S - Sale+OE | $5.27 | -1,255 | 4,192 | -23% | -$6,619 |
| D | 2022-12-09 | 2022-12-06 | TXMD | Glickman Mark A | Co-CEO | S - Sale+OE | $4.92 | -440 | 1,294 | -25% | -$2,165 |
| D | 2022-12-09 | 2022-12-06 | TXMD | Glickman Mark A | Co-CEO | M - OptEx | $0.00 | +1,734 | 1,734 | New | $0 |
| DM | 2022-12-09 | 2022-12-06 | TXMD | Donegan Michael C | CAO, Interim CFO, VP of Fin | M - OptEx | $0.00 | +3,476 | 4,288 | +428% | $0 |
| D | 2022-12-09 | 2022-12-06 | TXMD | Donegan Michael C | CAO, Interim CFO, VP of Fin | S - Sale+OE | $4.78 | -910 | 4,554 | -17% | -$4,350 |
| DM | 2022-12-09 | 2022-12-06 | TXMD | Walker Marlan D | GC | M - OptEx | $0.00 | +2,554 | 6,189 | +70% | $0 |
| D | 2022-12-09 | 2022-12-06 | TXMD | Walker Marlan D | GC | S - Sale+OE | $4.95 | -1,048 | 6,685 | -14% | -$5,188 |
| MI | 2022-12-09 | 2022-12-07+ | TXMD | Rosen David Efraim | 10% | P - Purchase | $5.66 | +20.4K | 1.74M | +1% | +$115.6K |
| 2022-12-08 | 2022-12-07 | TXMD | Naughton Gail K | Dir | S - Sale | $5.26 | -3,922 | 0 | -100% | -$20.6K | |
| I | 2022-10-31 | 2022-10-28 | TXMD | Rubric Capital Management LP | 10% | P - Purchase | $1,000.00 | +7,000 | 29.0K | +32% | +$7.00M |
| I | 2022-10-03 | 2022-09-30 | TXMD | Rubric Capital Management LP | 10% | P - Purchase | $1,000.00 | +7,000 | 22.0K | +47% | +$7.00M |
| D | 2022-08-22 | 2022-08-18 | TXMD | Naughton Gail K | Dir | M - OptEx | — | +1,984 | 3,922 | +102% | — |
| D | 2022-08-22 | 2022-08-18 | TXMD | BISARO PAUL | Dir | M - OptEx | — | +1,984 | 5,922 | +50% | — |
| D | 2022-08-22 | 2022-08-18 | TXMD | MUSING JULES A. | Dir | M - OptEx | — | +1,984 | 4,022 | +97% | — |
| D | 2022-08-22 | 2022-08-18 | TXMD | Russell Angus C. | Dir | M - OptEx | — | +1,984 | 5,792 | +52% | — |
| D | 2022-08-22 | 2022-08-18 | TXMD | Collins Cooper C. | Dir | M - OptEx | — | +1,984 | 46.7K | +4% | — |
| D | 2022-08-22 | 2022-08-18 | TXMD | Thompson Tommy G | Dir | M - OptEx | — | +2,976 | 5,954 | +100% | — |
| D | 2022-08-22 | 2022-08-18 | TXMD | Ling Karen | Dir | M - OptEx | — | +1,984 | 4,591 | +76% | — |
| MI | 2022-08-01 | 2022-07-29 | TXMD | Rosen David Efraim | 10% | P - Purchase | $25.86 | +580.0K | 1.72M | +51% | +$15.00M |
| MI | 2022-07-19 | 2022-07-15+ | TXMD | Rosen David Efraim | 10% | P - Purchase | $5.66 | +82.6K | 1.16M | +8% | +$467.5K |
| D | 2022-03-15 | 2022-03-14 | TXMD | Walker Marlan D | GC | M - OptEx | — | +230.0K | 258.9K | +796% | — |
| D | 2021-12-02 | 2021-11-30 | TXMD | Donegan Michael C | CAO, VP of Fin | S - Sale+OE | $0.54 | -29.8K | 99.4K | -23% | -$16.1K |
| D | 2021-12-02 | 2021-11-30 | TXMD | Donegan Michael C | CAO, VP of Fin | M - OptEx | — | +115.0K | 129.2K | +812% | — |
| 2021-11-22 | 2021-11-18 | TXMD | Collins Cooper C. | Dir | P - Purchase | $0.58 | +1.00M | 2.24M | +81% | +$580.0K | |
| M | 2021-08-19 | 2021-08-17+ | TXMD | Collins Cooper C. | Dir | P - Purchase | $0.725 | +1.00M | 1.24M | +422% | +$725.0K |
| 2021-08-19 | 2021-08-17 | TXMD | Ling Karen | Dir | P - Purchase | $0.75 | +33.4K | 130.3K | +35% | +$25.1K | |
| 2021-08-18 | 2021-08-16 | TXMD | BISARO PAUL | Dir | P - Purchase | $0.79 | +50.0K | 196.9K | +34% | +$39.5K | |
| I | 2021-08-17 | 2021-08-13 | TXMD | Thompson Tommy G | Dir | P - Purchase | $0.87 | +11.0K | 715.6K | +2% | +$9,570 |
| D | 2021-08-12 | 2021-08-10 | TXMD | Naughton Gail K | Dir | M - OptEx | — | +96.9K | 96.9K | New | — |
| D | 2021-08-12 | 2021-08-10 | TXMD | Thompson Tommy G | Dir | M - OptEx | — | +145.3K | 148.9K | +4,087% | — |
| D | 2021-08-12 | 2021-08-10 | TXMD | Russell Angus C. | Dir | M - OptEx | — | +96.9K | 190.4K | +104% | — |
| D | 2021-08-12 | 2021-08-10 | TXMD | MUSING JULES A. | Dir | M - OptEx | — | +96.9K | 101.9K | +1,937% | — |
| D | 2021-08-12 | 2021-08-10 | TXMD | CARROLL J MARTIN | Dir | M - OptEx | — | +96.9K | 106.9K | +969% | — |
| D | 2021-08-12 | 2021-08-10 | TXMD | Ling Karen | Dir | M - OptEx | — | +96.9K | 96.9K | New | — |
| D | 2021-08-12 | 2021-08-10 | TXMD | Collins Cooper C. | Dir | M - OptEx | — | +96.9K | 236.9K | +69% | — |
| D | 2021-08-12 | 2021-08-12 | TXMD | DArecca James | CFO | S - Sale+OE | $0.87 | -93.3K | 123.8K | -43% | -$81.2K |
| D | 2021-08-12 | 2021-08-10 | TXMD | DArecca James | CFO | M - OptEx | — | +217.2K | 217.2K | New | — |
| D | 2021-08-12 | 2021-08-10 | TXMD | BISARO PAUL | Dir | M - OptEx | — | +96.9K | 146.9K | +194% | — |
Purchase Sale Sale after option exercise All abbreviations